Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Structure and Function of Platelets01:18

Structure and Function of Platelets

4.6K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.6K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.6K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unveiling the role of UGT enzymes in chemoresistance: a path to enhanced cancer pharmacotherapy.

Cancer drug resistance (Alhambra, Calif.)·2026
Same author

Clopidogrel Vs Aspirin Monotherapy for Secondary Prevention After Percutaneous Coronary Intervention: A Nationwide Cohort Study.

JACC. Asia·2026
Same author

Aspirin vs clopidogrel in chronic coronary syndromes: a meta-analysis of ethnic differences.

European heart journal·2026
Same author

2025 Acute Coronary Syndrome Guideline: Missing the Boat on <i>CYP2C19</i> Genotyping.

Journal of the American Heart Association·2026
Same author

Transcatheter aortic valve thrombosis.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026
Same author

Guided de-escalation of antiplatelet treatment in patients at high atherothrombotic risk presenting with acute coronary syndrome: a post hoc analysis of the TROPICAL-ACS trial.

European heart journal. Acute cardiovascular care·2025

Related Experiment Video

Updated: Mar 25, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Platelet Function Testing in Patients on Antiplatelet Medications.

Lisa Gross1, Dániel Aradi2, Dirk Sibbing1

  • 1Department of Cardiology, Ludwig-Maximilians-University, Munich, Germany.

Seminars in Thrombosis and Hemostasis
|February 18, 2016
PubMed
Summary

Platelet function testing after percutaneous coronary intervention (PCI) can predict thrombotic or bleeding risks. However, current trials show no benefit from adjusting antiplatelet therapy based on these results.

More Related Videos

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

890
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.5K

Related Experiment Videos

Last Updated: Mar 25, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K
Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

890
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.5K

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Dual antiplatelet therapy is recommended after percutaneous coronary intervention (PCI).
  • Individual responses to antiplatelet drugs vary, leading to high on-treatment platelet reactivity (HPR) or low on-treatment platelet reactivity.
  • HPR increases risks for stent thrombosis and myocardial infarction, while low reactivity is linked to bleeding events.

Purpose of the Study:

  • To review current evidence on platelet function testing in patients undergoing PCI.
  • To highlight the prognostic value of platelet function testing for ischemic and bleeding events.
  • To discuss the utility of platelet function testing in guiding treatment and potential reasons for negative trial outcomes.

Main Methods:

  • Review of current evidence on platelet function testing in PCI patients.
  • Analysis of prognostic value for ischemic and bleeding events.
  • Discussion of treatment guidance and trial result explanations.

Main Results:

  • Platelet function testing shows prognostic value for both thrombotic and bleeding events.
  • Despite some evidence from small studies, large randomized controlled trials have not demonstrated improved outcomes from adjusting antiplatelet therapy based on platelet function testing.
  • Explanations for negative trial results are explored.

Conclusions:

  • Platelet function testing provides valuable prognostic information in PCI patients.
  • Current evidence does not support routine modification of antiplatelet therapy based on platelet function testing results.
  • Future research may clarify the role of individualized antiplatelet regimens guided by platelet function testing in high-risk populations.